Corpus overview


Overview

MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus


SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 4 records in total 4
    records per page




    Neonatal COVID-19 MESHD in French Guiana, a Case-Control study.

    Authors: Narcisse Elenga; Wandji Marie-Josephine; Julie Siban; Mathieu Nacher; Magalie Demar

    doi:10.21203/rs.3.rs-147493/v1 Date: 2021-01-14 Source: ResearchSquare

    BackgroundThis study aims to assess the risk of transmission of Severe Acute Respiratory Syndrome Coronavirus 2 MESHD ( SARS COV-2 MESHD) to newborns in the context of breastfeeding practice as part of routine care.MethodsIn this prospective study, we identified neonates born between May 14th and August 31st, 2020, to mothers who tested positive for SARS-CoV-2 at the time of delivery. From the cohort of 974 deliveries, we performed a nested case-control study. ResultsDuring the study period, 133 (13.7%) were positive by RT‐PCR for SARS‐CoV‐2. Among the 35 pregnant women with symptomatic COVID-19 MESHD (26.3%), cough MESHD was the most common symptom, occurring in half of the cases. Among them, 3 developed fever MESHD as other symptoms during hospitalization and 4 have progressed to critical pneumonia MESHD requiring transfer to intensive care unit. Among the neonates born from mothers with positive RT‐PCR for SARS‐CoV‐2, 32 were tested for SARS-COV-2 at 48 hours-7 days. Of them, 3 asymptomatic neonates tested positive. There were no significant differences in fetal distress, meconium-stained amniotic fluid, preterm birth, and neonatal asphyxia MESHD between the two groups Most infants were breastfed at birth, regardless of their mothers' COVID-19 MESHD status. In COVID-19 MESHD-positive pregnant women admitted to intensive care unit, the proportion of preterm births ( OR=12.5 [1.7-90.5]), fetal death MESHD in utero (OR=25.9 [2.2-305]) and admission in neonatal intensive care unit admission (OR=13.4 [3.0-60]), appeared higher than the controls. No maternal deaths were recorded.ConclusionsOur data suggest that under breastfeeding conditions with rigorous hygiene precautions and parental education, the risk of vertical transmission of the SARS-COV-2 virus is unlikely.

    Persistence of SARS-CoV-2 in the first trimester placenta leading to vertical transmission and fetal demise from an asymptomatic mother

    Authors: Prajakta Shende; Pradip Gaikwad; Manisha Gandhewar; Pawankumar Ukey; Anshul Bhide; Vainav Patel; Sharad Bhagat; Vikrant Bhor; Smita Mahale; Rahul Gajbhiye; Deepak Modi

    doi:10.1101/2020.08.18.20177121 Date: 2020-08-21 Source: medRxiv

    Coronaviruses infect the respiratory tract and are known to survive in these tissues during the clinical course of infection. However, how long can SARS-CoV-2 survive in the tissues is hitherto unknown. Herein, we report a case where the virus is detected in the first trimester placental cytotrophoblast and syncytiotrophoblasts five weeks after the asymptomatic mother cleared the virus from the respiratory tract. This first trimester placental infection was vertically transmitted as the virus was detected in the amniotic fluid and fetal membranes. This congenitally acquired SARS-CoV-2 infection MESHD was associated with hydrops and fetal demise. This is the first study providing concrete evidences towards persistent tissue infection of SARS-CoV-2 MESHD, its congenital transmission in early pregnancy leading to intrauterine fetal death MESHD.

    Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 MESHD in Kuwait

    Authors: Amal Ayed; Alia Embaireeg; Asmaa Benawadth; Wadha Al-Fouzan; Majeda Hammoud; Monif Alhathal; Abeer Alzaydai; Mariam Ayed

    doi:10.1101/2020.07.10.20150623 Date: 2020-07-14 Source: medRxiv

    Background: In late December of 2019, a novel coronavirus (SARS-CoV-2) was identified in the Chinese city Wuhan among a cluster of pneumonia MESHD patients. While it is known that pregnant women have reduced immunity and they are at risk for COVID-19 MESHD infection during the current pandemic, it is not clear if the disease manifestation would be different in pregnant women from non-pregnant women. Objectives: To describe the maternal and neonatal clinical features as well as outcome of pregnancies complicated with SARS-CoV-2 infection MESHD. Methods: In this retrospective national-based study, we analyzed the medical records of all SARS-CoV-2 positive pregnant patients and their neonates who were admitted to New-Jahra Hospital, Kuwait, between March 15th 2020 and May 31st 2020. The outcomes of pregnancies were assessed until the end date of follow-up (June 15th 2020). Results: A total of 185 pregnant women were enrolled with a median age of 31 years (interquartile range, IQR: 27.5-34), and median gestational age at diagnosis was 29 weeks (IQR: 18-34). The majority (88%) of the patients had mild symptoms, with fever MESHD (58%) being the most common presenting symptom followed by cough (50.6%). During the study period, 141 (76.2%) patients continued their pregnancy, 3 (1.6%) had a miscarriage, 1 (0.5%) had intrauterine fetal death MESHD and only 2 (1.1%) patients developed severe pneumonia MESHD and required intensive care. Most of the neonates were asymptomatic, and only 2 (5%) of them tested positive on day 5 by nasopharyngeal swab testing. Conclusion: Pregnant women do not appear to be at higher risk to the COVID-19 MESHD than the general population. The clinical features of pregnant women with SARS-CoV-2 infection MESHD were similar to those of the general population having SARS-CoV-2 infection MESHD. Favorable maternal and neonatal outcomes reinforce the existing evidence and may guide healthcare professionals in the management of pregnancies complicated with SARS-CoV-2 infection MESHD.

    Clinical manifestations and perinatal outcomes of pregnant women with COVID-19 MESHD: a systematic review and meta-analysis

    Authors: Jeong Yee; Woorim Kim; Ji Min Han; Ha Young Yoon; Nari Lee; Kyung Eun Lee; Hye Sun Gwak

    doi:10.21203/rs.3.rs-29550/v1 Date: 2020-05-18 Source: ResearchSquare

    This systematic review and meta-analysis aimed to evaluate the impact of COVID-19 MESHD on pregnant women. We searched for qualified studies in PubMed, Embase, and Web of Science. The clinical characteristics of pregnant women with COVID-19 MESHD and their infants were reported as means and proportions with 95% confidence interval (CI). Nine studies involving with 93 pregnant women with COVID-19 MESHD and 103 infants were included in the meta-analysis. Pregnant women with COVID-19 MESHD have relatively mild symptoms. However, abnormal proportions of laboratory parameters were similar or even increased, compared to general population. Around 30% of pregnant women with COVID-19 MESHD experienced preterm delivery, whereas the mean birth weight was 3214.7g. Fetal death MESHD, severe neonatal asphyxia MESHD, and detection of SARS-CoV-2 were observed in about 2%, whereas no neonatal death was found. In conclusion, the current review will serve as an ideal basis for future considerations in the treatment and management of COVID-19 MESHD in pregnant women.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.